Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
1. A beta-lactamase formulation comprising at least one particle with each particle comprising:
about 0.1-1% beta-lactamase;
about 0.1-1% hydroxypropylmethylcellulose acetate succinate (HPMCAS);
about 5-15% ethylcellulose dispersion;
about 0.1-1% sodium stearyl fumarate;
about 0.1-1% buffer;
about 0.5-5% trehalose; and
about 80-90% water.
2. The formulation of claim 1 , wherein the beta-lactamase comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence selected from SEQ ID NO: 1 and SEQ ID NO: 5.
3. The formulation of claim 1 , wherein the beta-lactamase comprises an amino acid sequence having at least 98% sequence identity with the amino acid sequence selected from SEQ ID NO: 1 and SEQ ID NO: 5.
4. The formulation of claim 1 , wherein the beta-lactamase comprises an amino acid sequence of SEQ ID NO: 1, having asparagine (N) replacing aspartic acid (D) at position 276, according to Ambler classification.
5. The formulation of claim 1 , wherein the beta-lactamase comprises an amino acid sequence of SEQ ID NO: 1, having asparagine (N) replacing aspartic acid (D) at position 276 and having glycine (G) replace alanine (A) at position 232 and having serine (S) replacing alanine (A) at position 237 and having glycine (G) replacing alanine (A) at position 238 and having aspartic acid (D) replacing serine (S) at position 240, according to Ambler classification.
6. The formulation of claim 1 , wherein the buffer is sodium hydrogen phosphate.
7. A beta-lactamase formulation comprising at least one pellet with each pellet comprising:
about 0.5% by weight beta-lactamase, the beta-lactamase comprises an amino acid sequence having at least 95% identity with the amino acid sequence selected from SEQ ID NO: 1 and SEQ ID NO: 5;
about 0.3% hydroxypropylmethylcellulose acetate succinate (HPMCAS);
about 10.1% ethylcellulose dispersion;
about 0.2% sodium stearyl sodium stearyl fumarate;
about 0.1% buffer;
about 1.0% trehalose; and
about 88.8% water.
8. The formulation of claim 7 , wherein the beta-lactamase comprises an amino acid sequence of SEQ ID NO: 1, having asparagine (N) replacing aspartic acid (D) at position 276, according to Ambler classification.
9. The formulation of claim 7 , wherein the beta-lactamase comprises an amino acid sequence of SEQ ID NO: 1, having asparagine (N) replacing aspartic acid (D) at position 276 and having glycine (G) replace alanine (A) at position 232 and having serine (S) replacing alanine (A) at position 237 and having glycine (G) replacing alanine (A) at position 238 and having aspartic acid (D) replacing serine (S) at position 240, according to Ambler classification.
10. The formulation of claim 7 , wherein the buffer is sodium hydrogen phosphate.
11. A method of preventing an antibiotic-associated adverse effect in a subject in need thereof, comprising administering the formulation of claim 1 ,
wherein the antibiotic is an oral antibiotic, the oral antibiotic being a substrate for the beta-lactamase; and
wherein the subject is undergoing treatment with the oral antibiotic.
12. The method of claim 11 , wherein the antibiotic-associated adverse effect is Clostridium difficile infection.
13. The method of claim 11 , wherein the antibiotic-associated adverse effect is antibiotic associated diarrhea.
14. The method of claim 11 , wherein the beta-lactamase comprises an amino acid sequence of SEQ ID NO: 1, having asparagine (N) replacing aspartic acid (D) at position 276, according to Ambler classification.
15. The method of claim 11 , wherein the beta-lactamase comprises an amino acid sequence of SEQ ID NO: 1, having asparagine (N) replacing aspartic acid (D) at position 276 and having glycine (G) replace alanine (A) at position 232 and having serine (S) replacing alanine (A) at position 237 and having glycine (G) replacing alanine (A) at position 238 and having aspartic acid (D) replacing serine (S) at position 240, according to Ambler classification.
16. The formulation of claim 11 , wherein the buffer is sodium hydrogen phosphate.
17. A method of preventing an antibiotic-associated adverse effect in a subject in need thereof, comprising administering the formulation of claim 7 ,
wherein the antibiotic is an oral antibiotic, the oral antibiotic being a substrate for the beta-lactamase; and
wherein the subject is undergoing treatment with the oral antibiotic.
18. The method of claim 17 , wherein the antibiotic-associated adverse effect is Clostridium difficile infection.
19. The method of claim 17 , wherein the antibiotic-associated adverse effect is antibiotic associated diarrhea.